Catalyst
Slingshot members are tracking this event:
Genfit (GNFT) NASH program using Elafibranor (GFT505) to treat Nonalcoholic Steatohepatitisplans on track to complete Phase 2 pharmacokinetic (PK) and pharmacodynamic (PD) data analysis in the second half of 2017
Do you think this event is important to the companies below? How will it affect their stock price?
Slingshot Insights Explained
Catalyst Date
Occurred on:
Sep 20, 2017
Occurred Source:
http://www.genfit.com/wp-content/uploads/2017/09/2017.09.20-PR-GENFIT-Lanifibranor.pdf
Related Projects
-
Don’t see a project related to the catalyst you care about?
Related Keywords
Pharmacokinetic (pk) And Pharmacodynamic (pd), Elafibranor, Gft505, Nonalcoholic Steatohepatitis, Phase 2b Interim Analysis
